Cendakimab  (Synonyms: RPC 4046; ABT 308; CC-93538)

Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC₅₀s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis)^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

Cendakimab (RPC4046; ABT 308; CC-93538) fully neutralizes IL-13-induced thymus and activation-regulated chemokine from lung epithelial A-549 cells with potencies ranging from 80 to 513 pM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2151032-62-9

Liquid

Colorless to light yellow

[Cendakimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human IL-13 Protein can bind Cendakimab. The EC₅₀ for this effect is 21.70 ng/mL.

• [1]. Catherine S Tripp, et al. RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study. Adv Ther. 2017 Jun;34(6):1364-1381.  [Content Brief]